Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Upphörande av somatostatinanaloger efter PRRT i neuroendokrina tumörer i mitten av tarmen (STOPNET)

9 november 2026 uppdaterad av: Australasian Gastro-Intestinal Trials Group

En randomiserad studie av upphörande av somatostatinanaloger efter peptidreceptorradionuklidterapi i neuroendokrina tumörer i mitten av tarmen (STOPNET)

Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms. However, approximately 75% of NETs are considered non-functional meaning that they do not result in hormone overproduction. The main treatment for both functional and non-functional NETs is somatostatin analogues (SSA, a type of inhibitory hormone). These drugs slow tumour growth and reduce hormone production. Over time, the majority of patients will experience tumour growth despite treatment with SSA therapy. When this occurs, the addition of Peptide Receptor Radionuclide Therapy (PRRT, a type of targeted radiotherapy) in combination with ongoing SSA therapy is given. However, it is not known if continuing SSA therapy after commencement of PRRT is beneficial or not.

The aim of this study is to estimate the outcomes of patients with grade 1 and 2 well differentiated mid, hind-gut or pancreatic neuroendocrine tumours who have progressed on SSA therapy and receive subsequent PRRT with or without concurrent SSA.

Studieöversikt

Detaljerad beskrivning

Neuroendocrine tumours commonly originate from the gut and metastasise widely including to the liver, lymph nodes and bones. Originally called "carcinoid tumours", these cancers are most commonly treated with somatostatin analogues (SSA) first line. These analogues treat carcinoid syndrome and slow tumour growth. Despite SSA therapy, progression develops over time. Upon progression, peptide receptor radionuclide therapy (PRRT) is the next standard therapeutic option. After PRRT is initiated, it is unclear if continuing SSA injections is beneficial. There are reasons to believe it might be necessary to continue SSAs, but other reasons to believe they should cease. Given that SSA injections are expensive and associated with side effects, this study aims to clarify the utility of continuing SSA injections after progression on SSA therapy and commencement of PRRT.

STOPNET aims to explore outcomes in grade 1 and 2 mid, hind gut or pancreatic neuroendocrine tumours, that have progressed on SSA therapy, are eligible to receive PRRT and in whom the SSA is either continued or ceased after PRRT is commenced.

The two primary objectives include

  1. To estimate the 20-month progression free survival rate after PRRT commencement in patients who cease and who continue SSA.

  2. Feasibility as measured by:

    1. Recruitment rate and
    2. Patient acceptance of ceasing and staying off SSA over the 20 month follow up period.

The study design of STOPNET is prospective, randomised, non-comparative, open label, multicentre phase II study. Patients meeting the inclusion and exclusion criteria will be randomised, prior to commencing PRRT, to either continue or cease SSA treatment. Randomisation will occur centrally in REDCap by the AGITG STOPNET study team. Randomisation will be 2:1 (the majority being randomised to cease SSA) and will be stratified by WHO tumour grade (1 V 2), sites of metastases (visceral only verse visceral and bone) and institution.

Studietyp

Interventionell

Inskrivning (Beräknad)

78

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • New South Wales
    • Queensland
      • Brisbane, Queensland, Australien, 4006
      • Cairns, Queensland, Australien, 4870
      • Toowoomba, Queensland, Australien, 4350
    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Rekrytering
        • The Queen Elizabeth Hospital
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Prof Timothy Price
    • Victoria
      • Melbourne, Victoria, Australien, 3000
        • Rekrytering
        • Peter MacCallum Cancer Centre
        • Kontakt:
        • Huvudutredare:
          • Dr Hui-Li Wong
        • Kontakt:
    • Western Australia
      • Kalgoorlie-Boulder, Western Australia, Australien, 6430
      • Perth, Western Australia, Australien, 6150
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 1Z2
        • Rekrytering
        • Cross Cancer Institute
        • Kontakt:
        • Huvudutredare:
          • Dr Stella Koumna
    • British Columbia
      • Vancouver, British Columbia, Kanada, V5Z 4E6
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • Rekrytering
        • London Health Sciences Centre Research Institute (LHSCRI)
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Dr David Laidley
      • Ottawa, Ontario, Kanada, K1Y 1J8
        • Rekrytering
        • Ottawa Hospital Research Institute
        • Kontakt:
        • Huvudutredare:
          • Dr Rachel Goodwin
      • Toronto, Ontario, Kanada, M5G 2M9
        • Rekrytering
        • University Health Network Princess Margaret Cancer Centre
        • Kontakt:
        • Huvudutredare:
          • Dr Raymond Jang
      • Toronto, Ontario, Kanada, TG 260
        • Rekrytering
        • Odette Cancer Centre Sunnybrook Health Sciences Centre
        • Kontakt:
        • Huvudutredare:
          • Dr Sten Myrehaug
    • Saskatchewan
      • Regina, Saskatchewan, Kanada, S4T 7T1
        • Rekrytering
        • Allan Blair Cancer Centre
        • Kontakt:
        • Huvudutredare:
          • Dr Mussawar Iqbal
      • Saskatoon, Saskatchewan, Kanada, S7N 4H
        • Rekrytering
        • Saskatoon Cancer Centre
        • Kontakt:
        • Huvudutredare:
          • Dr Mita Manna

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Adults over 18 years of age with well or moderately differentiated mid or hindgut neuroendocrine tumour, or pancreatic neuroendocrine tumour; metastatic and inoperable, demonstrating progression despite SSA treatment of sufficient disease magnitude to warrant PRRT as determined by the treating clinician and/or the NET Multidisciplinary Team (MDT). See section 4.1 regarding the recording of the reason(s).

  2. Must have measurable disease on triphasic CT/MRI as per RECIST 1.1.

  3. Ki67 ≤20% AND mitotic count ≤20 per HPF (i.e., WHO grade 1 or 2).

    • Note: Participants are eligible if only a single proliferation index has been performed due to local institutional practice, provided that the results are consistent with WHO grade 1 or 2 NET. However, if the results for both Ki67 and mitotic count are available, both results will need to be reported and are subject to eligibility assessment.

  4. Non-functioning NET: SSA treatment will have been commenced for control of tumour growth and not for carcinoid or other hormone overproduction syndrome, as judged by the clinician and/or NET MDT. Non-functioning NET is judged by the treating clinical team based on patient symptomatology.

    In addition, for this study, non-functioning tumour is defined as:

    • Never had escalation of the SSA treatment dose to control carcinoid or other hormone-related symptoms.

    • Never required short acting SSA treatment to control carcinoid or other hormone-related symptoms.

    • For mid and hind gut (GI cohort) patients:

      • 24-hour urine 5-hydroxyindoleacetic acid (5HIAA) <3x upper limit of normal.
      • No significant carcinoid induced valvular heart disease. I.e. Echocardiogram to be within 12 weeks of study randomisation, and deemed safe to proceed with PRRT by the treating team.
    • Note: routine measurement of gastrin, insulin, C-peptide levels, glucagon etc. is not required unless clinically indicated.

  5. Patient has been receiving growth-controlling doses of SSA for at least 12 weeks prior to study enrolment, for example a minimum of 30mg Octreotide or 120mg Lanreotide monthly. However, other SSA formulations used at growth-controlling doses are also eligible.

  6. Uptake on SSTR PET scan demonstrating somatostatin receptor expression that is suitable for PRRT as judged by the clinical team. FDG PET scans are to be done at the judgement of the treating team and are not required for enrolment into this study.

  7. PRRT is deemed the most appropriate next treatment step (i.e., patient is inoperable, and liver directed therapies are not preferred).

  8. ECOG performance status 0-2.

  9. Written informed consent. Patients must be willing to either cease or continue SSA, depending on which study arm they are randomised to. Patients must be willing to comply with all other study requirements.

  10. Adequate renal, hepatic and haematologic function as judged by the treating team.

  11. Life expectancy of at least 12 months.

Exclusion Criteria:

  1. This study is for pancreatic, mid-gut and hind-gut NET only. Gastric and lung NETs are excluded.
  2. Any patient on an SSA dose lower than the standard growth-control dose. Patients must have been on an SSA equivalent to Octreotide 30mg or Lanreotide 120mg for at least 3 months prior to study enrolment.
  3. Prior chemotherapy or targeted therapy (e.g., everolimus). Patients who have received prior local therapy, including external beam radiotherapy and liver directed therapy prior to or during SSA therapy are eligible.
  4. Any contraindication to PRRT, as per local institutional practice.
  5. Pregnancy. For female patients of childbearing potential and male patients with a female partner who is of childbearing potential, contraception and counselling is required.
  6. Prior PRRT. Patients being considered for re-treatment with PRRT are not eligible.
  7. Uncontrolled central nervous system metastases. Patients must have completed any surgery or radiation at least 4 weeks prior to enrolment and must be off corticosteroids for at least 2 weeks.
  8. Any patient, in the opinion of the investigator, who will not comply with study assessments and follow up visits. These might include any social, psychological, or geographical concerns, including alcohol/drug abuse.
  9. Any poorly controlled concurrent medical illness that may prevent the patient from complying with study assessments and follow up. This is to be judged by the treating team.
  10. Any concurrent or prior malignancy that, in the opinion of the treating team, may interfere with study assessments and endpoints.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Continue SSA

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Patients randomised to continue SSA will receive SSA injection 28 days (+/- 7 days) prior to the first PRRT cycle, and continue to receive SSA every 28 days (+/- 7 days) during and after the completion of PRRT.

Andra namn:
  • SSA fortsättning
Experimentell: Cease SSA

Patients randomised to cease SSA will receive SSA injection ≥28 days prior to their first cycle of PRRT. Patients will not receive any further long acting SSA injections after this time.

Patients randomised to cease SSA will receive their last SSA injection ≥28 days prior to their first cycle of PRRT and will remain off SSA for the duration of the study. If there is concern from the treating team that a patient may experience a carcinoid flare after PRRT, then short acting octreotide is allowed to be used to control any symptoms.

Andra namn:
  • SSA upphörande

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
20-month progression free survival rate after PRRT
Tidsram: 20 months

Estimate the 20-month progression free survival rate after PRRT in patients who cease and who continue SSA.

20 months
Assess the barriers which would impede the feasibility of a subsequent phase 3 trial
Tidsram: 20 months
  1. Proportion of participants that remained on the SSA cessation arm for the duration of the 20-month study follow up (patient acceptance of SSA cessation).
  2. Rate of recruitment: ability to complete recruitment over the 24-month recruitment period
20 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Measure Quality of life using the European Organisation For Research And Treatment Of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30) scales
Tidsram: 20 months

Responses to the QLQ-C30 scale from 0-100 using EORTC guidelines, with higher scores reflecting better level of functioning.

20 months
Measure Quality of life using the EORTC QLQ-GINET21 scales
Tidsram: 20 months

Responses to the QLQ-GINET21 scale from 0-100 using EORTC guidelines, with higher scores reflecting more severe symptoms.

20 months
Cost-effectiveness of SSA therapy cessation
Tidsram: The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.

Access to Medicare and PBS data to asses use of other healthcare providers, diagnostic tests and imaging services funded via public health care systems and use of pharmaceutical services respectively.

The MBS/PBS data will be obtained for the period six months prior to study entry, and until the end of 2 years follow-up post PRRT for patients who have provided consent.
Psycho-oncological impacts of SSA therapy cessation: Decision Regret
Tidsram: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of Decision Regret Scale from 1 - 5 (1-Strongly Agree, 2-Agree, 3-Neither Agree Nor Disagree, 4-Disagree, 5-Strongly Disagree)

20 months
Psycho-oncological impacts of SSA therapy cessation: Fear of Cancer Progression
Tidsram: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Fear of Cancer Progression Scale from 1 - 5 (1-Never, 2-Seldom, 3-Sometimes, 4-Often, 5-Very often)

20 months
Psycho-oncological impacts of SSA therapy cessation: Decisional Conflict
Tidsram: 20 months

Psycho-oncological impacts of SSA therapy cessation using the self-reported measures of the Decisional Conflict Scale from 0 - 4 (0-Strongly Agree, 1-Agree, 2-Neither Agree Nor Disagree, 3-Disagree, 4-Strongly Disagree)

20 months
Time to commencement of subsequent therapy
Tidsram: 20 months

Time to commencement of subsequent therapy (e.g re-challenge with PRRT, liver directed therapies, chemotherapy, targeted therapies)

20 months
Overall survival
Tidsram: 20 months

Estimate the 20-month overall survival rate in patients who cease and who continue SSA.

20 months
Rates of SSA being recommenced over time
Tidsram: 20 months

Cumulative percentage of SSA recommencement over time.

20 months

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Exploratory analyses
Tidsram: 20 months

Exploratory analyses including, but not limited to: Define and validate NET tissue and circulating biomarkers with a particular focus on miRNA.

20 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 oktober 2024

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 juni 2028

Studieregistreringsdatum

Först inskickad

14 mars 2024

Först inskickad som uppfyllde QC-kriterierna

1 april 2024

Första postat (Faktisk)

3 april 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

12 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

9 november 2026

Senast verifierad

1 november 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

produkt tillverkad i och exporterad från U.S.A.

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera